Immunitybio provides updated status of biologics license application (bla) for vesanktiva plus bcg for patients with bcg-unresponsive non-muscle invasive bladder cancer carcinoma in situ

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a clinical-stage immunotherapy company, today announced that it has achieved a major milestone with over 80 subjects in the quilt-3.032 study completing at least 12 months of follow-up as of january 14, 2022. all data for quilt-3.032, which is studying vesanktiva™ plus bcg in subjects with bcg-unresponsive non-muscle invasive bladder cancer carcinoma in situ (nmibc cis), have been locked and analyzed. the results continue t
IBRX Ratings Summary
IBRX Quant Ranking